CompletedPhase 2NCT00080535

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

Studying Primary cutaneous T-cell lymphoma

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: National Cancer Institute (NCI)
Principal Investigator: Robert J Kreitman, M.D.
National Cancer Institute, National Institutes of Health
Intervention: LMB-2(biological)
Enrollment: 10 enrolled
Eligibility: 18 years · All sexes
Timeline: 2004 – 2011

Study locations (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00080535 on ClinicalTrials.gov

Other trials for Primary cutaneous T-cell lymphoma

Additional recruiting or active studies for the same condition.

RECRUITINGNANCT07021495
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
Leiden University Medical Center

See all trials for Primary cutaneous T-cell lymphoma →

← Back to all trials